secwatch.observer — SEC 8-K summary
======================================

Issuer:     LeonaBio, Inc. (LONA)
CIK:        0001620463
Form:       8-K
Filed at:   2026-08-26T20:05:16+00:00
Accession:  0001193125-26-368288
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

LeonaBio enrolls 500th subject in Phase 3 ELAINE-3 trial; triggers warrant exercise
--------------------------------------------------------------------------------

- Enrolled 500th subject in Phase 3 ELAINE-3 trial (NCT05696626) for lasofoxifene + abemaciclib in ER+/HER2- ESR1-mutated metastatic breast cancer.
- Milestone triggers exercisability of 23,031,494 Series A Common Warrants at $6.35/share from Dec 2025 private placement.
- Full exercise would raise ~$146.2M; warrants expire 30 days after initial exercise date, no later than Nov 30, 2026.
- Warrants exercisable cash or cashless if resale registration unavailable; initial exercise date set as of Aug 26, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1620463/000119312526368288/0001193125-26-368288-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1620463/000119312526368288/lona-20260826.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-368288

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer